Astraveus Advances Lakhesys Cell Therapy System With Expert Hospital Evaluation

According to a recent LinkedIn post from Astraveus, clinicians from Institut Paoli-Calmettes in Marseille visited the company in Paris to conduct a structured, two‑day expert evaluation of its Lakhesys cell therapy manufacturing system. The visitors reportedly brought significant hands‑on experience in cell therapy production and analytics and focused on usability and workflow fit in a point‑of‑care manufacturing context.

The post suggests that this was the first formal expert evaluation of the Lakhesys prototype, positioned as a stress test before entering more formal evaluation phases. By inviting additional users to join evaluation programs, Astraveus appears to be seeking broader real‑world feedback that could de‑risk subsequent validation, shorten time to clinical adoption, and strengthen its competitive position in automated cell therapy manufacturing.

For investors, early engagement with a leading cancer center may signal progress toward product‑market fit in a highly technical, regulated niche. If the feedback translates into a more robust, user‑aligned platform, Astraveus could improve its prospects for partnerships with hospitals and therapy developers, potentially supporting future revenue generation from hardware, consumables, and service contracts.

The focus on point‑of‑care environments also indicates an emphasis on decentralized manufacturing models, an area of growing interest in cell and gene therapy. Successful alignment with such workflows could position Lakhesys as an enabling technology for centers seeking to internalize or scale cell therapy production, which may enhance Astraveus’s strategic value in the oncology and advanced therapies ecosystem.